Ribociclib plus Fulvestrant in Advanced Breast Cancer Reply

被引：0
|
作者：
Slamon, Dennis J. [1 ]
Jerusalem, Guy [2 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Univ Liege, Liege, Belgium
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 382卷 / 23期
关键词：
THERAPY;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Ribociclib plus Fulvestrant in Advanced Breast Cancer
    Hindie, Elif
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (23):
  • [2] Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
    Slamon, Dennis J.
    Neven, Patrick
    Chia, Stephen
    Fasching, Peter A.
    De Laurentiis, Michelino
    Im, Seock-Ah
    Petrakova, Katarina
    Bianchi, Giulia V.
    Esteva, Francisco J.
    Martin, Miguel
    Nusch, Arnd
    Sonke, Gabe S.
    De la Cruz-Merino, Luis
    Beck, J. Thaddeus
    Pivot, Xavier
    Sondhi, Manu
    Wang, Yingbo
    Chakravartty, Arunava
    Rodriguez-Lorenc, Karen
    Taran, Tetiana
    Jerusalem, Guy
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (06): : 514 - 524
  • [3] Ribociclib plus fulvestrant in the treatment of breast cancer
    Neven, Patrick
    Sonke, Gabe S.
    Jerusalem, Guy
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (01) : 93 - 106
  • [4] Ribociclib and Fulvestrant Combination for Patients with advanced Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (10)
  • [5] Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer
    Tolaney, Sara M.
    Im, Young-Hyuck
    Calvo, Emiliano
    Lu, Yen-Shen
    Hamilton, Erika
    Forero-Torres, Andres
    Bachelot, Thomas
    Maur, Michela
    Fasolo, Angelica
    Tiedt, Ralph
    Nardi, Lisa
    Stammberger, Uz
    Abdelhady, Ahmed M.
    Ruan, Shiling
    Lee, Soo Chin
    CLINICAL CANCER RESEARCH, 2021, 27 (02) : 418 - 428
  • [6] Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
    Colombo, Giorgio Lorenzo
    Valentino, Maria Chiara
    Fabi, Alessandra
    Dieci, Maria Vittoria
    Caruggi, Mauro
    Bruno, Giacomo Matteo
    Lombardi, Gloria
    Di Matteo, Sergio
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2023, 19 : 301 - 312
  • [7] Capivasertib plus fulvestrant in advanced breast cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (09) : 1057 - 1057
  • [8] Ribociclib plus fulvestrant in postmenopausal women with HR+, HER2-advanced breast cancer (ABC)
    Tolaney, S. M.
    Forero-Torres, A.
    Boni, V.
    Bachelot, T.
    Lu, Y-S
    Maur, M.
    Fasolo, A.
    Motta, M.
    Pan, C.
    Dobson, J.
    Hewes, B.
    Lee, S. Chin
    CANCER RESEARCH, 2017, 77
  • [9] Fulvestrant plus capivasertib for metastatic breast cancer Reply
    Jones, Robert H.
    Casbard, Angela
    Carucci, Margherita
    Foxley, Andrew
    Howell, Sacha J.
    LANCET ONCOLOGY, 2020, 21 (05): : E234 - E234
  • [10] Inavolisib plus palbociclib and fulvestrant in advanced breast cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2025, 85 (03) : 232 - 232
12345